Cobro Ventures

AI Proteins is a biotechnology company established in 2021, headquartered in Boston, Massachusetts. It specializes in designing and engineering synthetic mini protein therapeutics using artificial intelligence-based platforms.

Regenacy Pharmaceuticals is a Boston-based biopharmaceutical company founded in 2016 that develops therapies for peripheral neuropathies, hemoglobinopathies and certain oncology indications. Its approach centers on restoring normal protein function with oral, isoform-selective histone deacetylase inhibitors. The company is advancing drug programs that include ricolinostat to address sickle cell disease and beta-thalassemia, as well as additional HDAC inhibitor–based therapies for neuropathies and related conditions.

NextRNA Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2020. The company focuses on developing targeted therapeutics by discovering novel non-coding ribonucleic acids (ncRNAs) linked to various diseases. Utilizing an innovative discovery platform, NextRNA identifies and modulates RNA-binding proteins associated with disease functions of ncRNAs. This approach aims to disrupt the interactions between disease-related ncRNAs and their protein partners, thereby enabling medical practitioners to address and potentially cure a range of diseases.

Windgap Medical Inc. is a biotechnology company based in Massachusetts that specializes in the manufacture of compact epinephrine autoinjectors designed for the treatment of anaphylaxis, a severe allergic reaction. Established in 2011, the company develops innovative medical devices that are filled with heat-stable epinephrine, enhancing the temperature resilience and shelf life of the medication. These autoinjectors enable healthcare professionals to effectively administer epinephrine to patients experiencing acute allergy attacks, thereby improving treatment outcomes in critical situations. Windgap Medical is committed to addressing the needs of patients with severe allergies through its advanced drug delivery solutions.

TechsoMed is an Israeli medical device company specializing in the development of ultrasound-based real-time monitoring systems for thermal ablation procedures. These procedures have wide-ranging applications, including tumor destruction, treatment of heart arrhythmias, and blood pressure management. Despite a market size in the billions, these procedures often suffer from high failure rates due to the lack of real-time monitoring capabilities. TechsoMed's technology addresses this issue by providing physicians with the ability to monitor tissue destruction in real time, thereby enhancing the effectiveness of these minimally invasive and cost-effective treatments for patients, physicians, and insurance companies alike.

MANA Therapeutics is a biotechnology company focused on developing innovative cell therapies aimed at treating cancer. The company’s primary objective is to harness and educate immune cells to effectively combat cancer, thereby offering patients a more durable and economically viable treatment option. MANA Therapeutics' therapies are designed to eliminate cancer cells while empowering the body's endogenous immune system to recognize and fight the disease over the long term. Through a dedicated team of scientists and physicians, the company strives to confer lifelong immunity against cancer, enhancing the overall effectiveness of cancer treatments and improving patient outcomes.

Regenacy Pharmaceuticals is a Boston-based biopharmaceutical company founded in 2016 that develops therapies for peripheral neuropathies, hemoglobinopathies and certain oncology indications. Its approach centers on restoring normal protein function with oral, isoform-selective histone deacetylase inhibitors. The company is advancing drug programs that include ricolinostat to address sickle cell disease and beta-thalassemia, as well as additional HDAC inhibitor–based therapies for neuropathies and related conditions.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.

MANA Therapeutics is a biotechnology company focused on developing innovative cell therapies aimed at treating cancer. The company’s primary objective is to harness and educate immune cells to effectively combat cancer, thereby offering patients a more durable and economically viable treatment option. MANA Therapeutics' therapies are designed to eliminate cancer cells while empowering the body's endogenous immune system to recognize and fight the disease over the long term. Through a dedicated team of scientists and physicians, the company strives to confer lifelong immunity against cancer, enhancing the overall effectiveness of cancer treatments and improving patient outcomes.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.

C4 Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutic candidates aimed at targeting and eliminating disease-causing proteins for the treatment of cancer, neurodegenerative diseases, and other conditions. The company's lead product candidate, CFT7455, is an orally bioavailable degrader targeting IKZF1/3, designed to treat multiple myeloma and various lymphomas. Additionally, C4 Therapeutics is advancing CFT8634, which targets BRD9 for synovial sarcoma and SMARCB1-deleted solid tumors, as well as programs targeting BRAF V600E and RET for genetically defined resistant solid tumors. The company employs its proprietary Degronimid platform, which utilizes small molecule binders to flag harmful proteins for degradation by the cellular proteasome system, allowing for the potential treatment of previously undruggable targets. Founded in 2015 and headquartered in Watertown, Massachusetts, C4 Therapeutics engages in strategic collaborations to enhance its research and development efforts.

Acetylon Pharmaceuticals, Inc. is a biopharmaceutical company based in Boston, Massachusetts, focused on developing small molecule drugs that target epigenetic mechanisms to enhance therapeutic outcomes in cancer and other serious diseases. Founded in 2008, Acetylon specializes in creating selective inhibitors of histone deacetylase (HDAC), utilizing its proprietary drug discovery platform to develop a portfolio of optimized compounds for oral administration. The company's lead drug candidates, ACY-1215 and ACY-241, are selective HDAC6 inhibitors currently undergoing clinical trials for the treatment of multiple myeloma. Acetylon aims to leverage its expertise in epigenetic regulation to address critical unmet medical needs in oncology and beyond.

OPNET Technologies, Inc., founded in 1986, specializes in software products and services designed for managing networks and applications. The company distinguishes itself by emphasizing analytics, which enable users to analyze collected data and transform it into actionable insights. Unlike traditional network management systems that primarily focus on data collection and monitoring historical trends, OPNET's solutions facilitate the rapid resolution of performance issues and proactively prevent potential problems. These issues may include network configuration errors, congestion, and inefficiencies between the network and applications. By providing advanced analytical capabilities, OPNET aims to enhance the performance and availability of critical networks and applications, ensuring that organizations can effectively manage their technology infrastructure.